Just as doctors use the patient's immune system to improve T cells for cancer, Rubius Therapeutics is using red blood cells to develop targeted therapies. The media reported that Torben Straight Nissen, CEO of Rubius Therapeutics, Inc. Think that their therapy is basically 'super blood' because the treatment uses red blood cells instead of chemicals or synthetic materials.
Rubius Therapeutics plans to use medical proteins equipped with red blood cells and make adjustments according to specific conditions. These special red blood cells are then injected into the patient to start treating the patient's illness. Ultimately, this super blood accounts for less than 1% of the patient's total blood volume.
Initially, the company hopes to develop super blood therapies to replace the missing enzymes in patients with rare diseases and to treat cancer and autoimmune diseases such as lupus and type 1 diabetes. However, unlike T cell therapy, red blood cell therapy Universal applicability. The Rubius Therapeutics website says that we only need a generic donor (a donor with type O blood) who can produce enough therapeutic doses to treat hundreds to thousands of different patients.
The company is gradually realizing its own goals. It has recently completed a fundraising of 100 million U.S. dollars. In June 2017, the company received 120 million U.S. dollars from investors.
Nissen pointed out in a research report that the increase in funding further consolidated the company's foundation and enabled us to speed up the development of the first red cell therapy (RCT) products. The goal of these products is to treat enzyme defects, cancer and autoimmune diseases. A strong team of investors, leaders, and consultants was convened to provide long-range planning and design for patients with novel cell therapy.
It may take some time for Rubius Therapeutics' therapy to be widely used. After all, the current is only a concept. First, these therapies must be developed and then confirmed through a series of clinical trials. If everything goes well, Super Blood will It was eventually approved by the U.S. Food and Drug Administration (FDA), just like the 2017 T cell therapy.